Literature DB >> 32858499

Diacerein: Recent insight into pharmacological activities and molecular pathways.

Maged Almezgagi1, Yu Zhang2, Kamal Hezam3, Emad Shamsan2, Mohammed Gamah4, Fadhl Al-Shaebi5, Abdul Baset Abbas6, Muhammad Shoaib2, Bassam Saif6, Ying Han7, Ruhan Jia7, Wei Zhang8.   

Abstract

Diacerein is a symptomatic slow-acting drug in osteoarthritis (SYSADOA) and the active metabolite is rhein. It is a non-steroidal anti-inflammatory drug with unique pharmacological properties as anti-oxidant and anti-apoptosis. Diacerein has recently shown to have a potential role by mediating anti-inflammatory as well as anti-oxidant and anti-apoptosis in kidney injury, diabetes mullites, and a beneficial effect on pain relief. It may have a therapeutic role in cancer, ulcerative colitis, testicular injury and cervical hyperkeratosis. Furthermore, diacerein has a valuable addition in combination therapy as a synergetic agent. This review, the first of its kind, highlights the proposed roles of diacerein in osteoarthritis and discusses recent results supporting its emerging roles with a particular focus on how these new insights may facilitate the rational development of diacerein for targeted therapies in the future.
Copyright © 2020. Published by Elsevier Masson SAS.

Entities:  

Keywords:  Anti-apoptosis; Anti-inflammatory; Anti-oxidant; Cytokines; Diacerein

Mesh:

Substances:

Year:  2020        PMID: 32858499     DOI: 10.1016/j.biopha.2020.110594

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  8 in total

1.  Diacerein, an inhibitor of IL-1β downstream mediated apoptosis, improves radioimmunotherapy in a mouse model of Burkitt's lymphoma.

Authors:  Javeria Zaheer; A Ram Yu; Hyeongi Kim; Hyun Ji Kang; Min Kyoung Kang; Jae Jun Lee; Jin Su Kim
Journal:  Am J Cancer Res       Date:  2021-12-15       Impact factor: 6.166

Review 2.  Osteoarthritis complications and the recent therapeutic approaches.

Authors:  Manal A Abdel-Aziz; Helmy M S Ahmed; Aziza A El-Nekeety; Mosaad A Abdel-Wahhab
Journal:  Inflammopharmacology       Date:  2021-11-09       Impact factor: 4.473

Review 3.  Effects of Anthraquinones on Immune Responses and Inflammatory Diseases.

Authors:  Dandan Xin; Huhu Li; Shiyue Zhou; Hao Zhong; Weiling Pu
Journal:  Molecules       Date:  2022-06-14       Impact factor: 4.927

4.  Diacerein Inhibits Myopia Progression through Lowering Inflammation in Retinal Pigment Epithelial Cell.

Authors:  Peng-Tai Tien; Chia-Hung Lin; Chih-Sheng Chen; Ching-Yao Chang; Hsiangyu Ku; Dekang Gan; Yi-Yu Tsai; Jamie Jiin-Yi Chen; Hui-Ju Lin; Lei Wan
Journal:  Mediators Inflamm       Date:  2021-07-03       Impact factor: 4.711

Review 5.  Overview of First-Line and Second-Line Pharmacotherapies for Osteoarthritis with Special Focus on Intra-Articular Treatment.

Authors:  Alicja Nowaczyk; Dawid Szwedowski; Ignacio Dallo; Jacek Nowaczyk
Journal:  Int J Mol Sci       Date:  2022-01-29       Impact factor: 5.923

6.  Interleukin-6 expression and its modulation by diacerein in a rat model of chronic stress induced cardiac dysfunction.

Authors:  Vipul Agarwal; Arjun Singh Kaushik; Mujeeba Rehman; Rishabh Chaudhary; Talha Jawaid; Mehnaz Kamal; Vikas Mishra
Journal:  Heliyon       Date:  2021-12-02

7.  Chondroitin sulfate-functionalized lipid nanoreservoirs: a novel cartilage-targeting approach for intra-articular delivery of cassic acid for osteoarthritis treatment.

Authors:  Heba M K Ebada; Maha M A Nasra; Rasha A Nassra; Ossama Y Abdallah
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.419

8.  Diacerein counteracts acetaminophen-induced hepatotoxicity in mice via targeting NLRP3/caspase-1/IL-1β and IL-4/MCP-1 signaling pathways.

Authors:  Mahmoud Elshal; Marwa E Abdelmageed
Journal:  Arch Pharm Res       Date:  2022-03-04       Impact factor: 4.946

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.